Literature DB >> 26900089

Prognostic value of diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography after concurrent chemoradiotherapy in uterine cervical cancer.

Jung Jae Park1, Chan Kyo Kim2, Byung Kwan Park1.   

Abstract

PURPOSE: To evaluate the prognostic value of diffusion-weighted imaging (DWI) and positron emission tomography/computed tomography (PET/CT) for predicting disease progression after concurrent chemoradiotherapy (CCRT) in cervical cancer.
MATERIALS AND METHODS: A total of 67 locally advanced cervical cancer patients who received CCRT underwent both DWI and PET/CT before and during (at 1month) treatment. The mean apparent diffusion coefficient (ADCmean) and maximum standardized uptake value (SUVmax) were measured on the tumor and the percentage changes between 2 time points (ΔADCmean and ΔSUVmax) were calculated. The ΔADCmean and ΔSUVmax were compared in terms of predicting disease progression after CCRT.
RESULTS: During a mean follow-up of 2.7years, disease progression was identified in 16 patients (23.9%). The ΔADCmean and ΔSUVmax were significantly correlated (Spearman correlation coefficient, 0.38; P=0.002). For predicting disease progression, the integrated area under the curves of ΔADCmean (0.791) and ΔSUVmax (0.781) were not significantly different (P=0.88). On multivariate analysis, both ΔADCmean and ΔSUVmax were the independent predictors of disease progression (hazard ratio, 7.9 and 8.7; P, 0.001 and <0.001, respectively).
CONCLUSION: The percentage changes of ADCmean and SUVmax during CCRT have a similar prognostic value for predicting disease progression after CCRT in cervical cancers.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Concurrent chemoradiotherapy; Diffusion-weighted imaging; Disease progression; PET/CT

Mesh:

Substances:

Year:  2016        PMID: 26900089     DOI: 10.1016/j.radonc.2016.02.014

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Moving Forward in Cervical Cancer: Enhancing Susceptibility to DNA Repair Inhibition and Damage, an NCI Clinical Trials Planning Meeting Report.

Authors:  Matthew M Harkenrider; Merry Jennifer Markham; Don S Dizon; Anuja Jhingran; Ritu Salani; Ramy K Serour; Jean Lynn; Elise C Kohn
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

2.  Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer.

Authors:  Si Gao; Siyao Du; Zaiming Lu; Jun Xin; Song Gao; Hongzan Sun
Journal:  Eur Radiol       Date:  2019-09-06       Impact factor: 5.315

3.  Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and HPV genotyping for stage IB-IV cervical cancer patients following chemoradiotherapy.

Authors:  Gigin Lin; Lan-Yan Yang; Yu-Chun Lin; Yu-Ting Huang; Feng-Yuan Liu; Chun-Chieh Wang; Hsin-Ying Lu; Hsin-Ju Chiang; Yu-Ruei Chen; Ren-Chin Wu; Koon-Kwan Ng; Ji-Hong Hong; Tzu-Chen Yen; Chyong-Huey Lai
Journal:  Eur Radiol       Date:  2018-07-26       Impact factor: 5.315

4.  Histogram analysis of apparent diffusion coefficients for predicting pelvic lymph node metastasis in patients with uterine cervical cancer.

Authors:  Jiyeong Lee; Chan Kyo Kim; Sung Yoon Park
Journal:  MAGMA       Date:  2019-09-23       Impact factor: 2.310

5.  Predicting factors for primary cervical cancer recurrence after definitive radiation therapy.

Authors:  Mitsuru Okubo; Tomohiro Itonaga; Tatsuhiko Saito; Sachika Shiraishi; Daisuke Yunaiyama; Ryuji Mikami; Akira Sakurada; Shinji Sugahara; Koichi Tokuuye; Kazuhiro Saito
Journal:  BJR Open       Date:  2021-11-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.